Professional Oral Care for Everolimus-Induced Oral Mucositis: Naoki Niikura, MD, PhD

In combination with exemestane, everolimus is an effective treatment for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. However, this treatment can often cause oral mucositis. This serious adverse event, characterized by the formation of ulcers, can cause difficulty in swallowing and speaking, necessitating dose reduction and treatment disruption if not properly managed. In their study now published in The Oncologist, Naoki Nii...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.